Key facts
- This page summarizes John B. Bode's Form 4 filing for ZEVRA THERAPEUTICS, INC. (ZVRA).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 15 Jul 2024, 16:10.
John B. Bode - 12 Jul 2024 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)
- Role
- Director
- Signature
- /s/ Timothy J. Sangiovanni, Attorney-in-Fact for John B. Bode
- Issuer symbol
- ZVRA
- Transactions as of
- 12 Jul 2024
- Net transaction value
- +$58,661
- Form type
- 4
- Filing time
- 15 Jul 2024, 16:10:52 UTC
- Previous filing
- 15 May 2024
- Next filing
- 21 Mar 2025
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
John B. Bode filed Form 4 for ZEVRA THERAPEUTICS, INC. (ZVRA) on 15 Jul 2024.
Change
- Previous filing in this sequence was filed on 15 May 2024.
- Current net transaction value: +$58,661.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported transactions
ZVRA
transaction
Common Stock
Purchase
- Transaction value
- $58,661
- Shares
- +10,000
- Change %
- +50%
- Price
- $5.87
- Shares after
- 30,000
- Date
- 12 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.81 to $5.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |